Global Metabolic Disorders Drugs Market Insights, Forecast to 2029

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Metabolic Disorders Drugs Product Introduction
• 1.2 Market by Type
  • 1.2.1 Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
  • 1.2.2 Glycogen Metabolism Disease Drug
  • 1.2.3 Lipid Metabolism Disease Drug
  • 1.2.4 Amino Acid Metabolism Drug
  • 1.2.5 Other
• 1.3 Market by Application
  • 1.3.1 Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
  • 1.3.2 Hospital
  • 1.3.3 Retail Pharmacy
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Metabolic Disorders Drugs Sales Estimates and Forecasts 2018-2029
• 2.2 Global Metabolic Disorders Drugs Revenue by Region
  • 2.2.1 Global Metabolic Disorders Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 2.2.2 Global Metabolic Disorders Drugs Revenue by Region (2018-2023)
  • 2.2.3 Global Metabolic Disorders Drugs Revenue by Region (2024-2029)
  • 2.2.4 Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2029)
• 2.3 Global Metabolic Disorders Drugs Sales Estimates and Forecasts 2018-2029
• 2.4 Global Metabolic Disorders Drugs Sales by Region
  • 2.4.1 Global Metabolic Disorders Drugs Sales by Region: 2018 VS 2022 VS 2029
  • 2.4.2 Global Metabolic Disorders Drugs Sales by Region (2018-2023)
  • 2.4.3 Global Metabolic Disorders Drugs Sales by Region (2024-2029)
  • 2.4.4 Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2029)
• 2.5 US & Canada
• 2.6 Europe
• 2.7 China
• 2.8 Asia (excluding China)
• 2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

• 3.1 Global Metabolic Disorders Drugs Sales by Manufacturers
  • 3.1.1 Global Metabolic Disorders Drugs Sales by Manufacturers (2018-2023)
  • 3.1.2 Global Metabolic Disorders Drugs Sales Market Share by Manufacturers (2018-2023)
  • 3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Metabolic Disorders Drugs in 2022
• 3.2 Global Metabolic Disorders Drugs Revenue by Manufacturers
  • 3.2.1 Global Metabolic Disorders Drugs Revenue by Manufacturers (2018-2023)
  • 3.2.2 Global Metabolic Disorders Drugs Revenue Market Share by Manufacturers (2018-2023)
  • 3.2.3 Global Top 10 and Top 5 Companies by Metabolic Disorders Drugs Revenue in 2022
• 3.3 Global Key Players of Metabolic Disorders Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• 3.4 Global Metabolic Disorders Drugs Sales Price by Manufacturers
• 3.5 Analysis of Competitive Landscape
  • 3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
  • 3.5.2 Global Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
• 3.6 Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Base Distribution and Headquarters
• 3.7 Global Key Manufacturers of Metabolic Disorders Drugs, Product Offered and Application
• 3.8 Global Key Manufacturers of Metabolic Disorders Drugs, Date of Enter into This Industry
• 3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

• 4.1 Global Metabolic Disorders Drugs Sales by Type
  • 4.1.1 Global Metabolic Disorders Drugs Historical Sales by Type (2018-2023)
  • 4.1.2 Global Metabolic Disorders Drugs Forecasted Sales by Type (2024-2029)
  • 4.1.3 Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• 4.2 Global Metabolic Disorders Drugs Revenue by Type
  • 4.2.1 Global Metabolic Disorders Drugs Historical Revenue by Type (2018-2023)
  • 4.2.2 Global Metabolic Disorders Drugs Forecasted Revenue by Type (2024-2029)
  • 4.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• 4.3 Global Metabolic Disorders Drugs Price by Type
  • 4.3.1 Global Metabolic Disorders Drugs Price by Type (2018-2023)
  • 4.3.2 Global Metabolic Disorders Drugs Price Forecast by Type (2024-2029)

5 Market Size by Application

• 5.1 Global Metabolic Disorders Drugs Sales by Application
  • 5.1.1 Global Metabolic Disorders Drugs Historical Sales by Application (2018-2023)
  • 5.1.2 Global Metabolic Disorders Drugs Forecasted Sales by Application (2024-2029)
  • 5.1.3 Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• 5.2 Global Metabolic Disorders Drugs Revenue by Application
  • 5.2.1 Global Metabolic Disorders Drugs Historical Revenue by Application (2018-2023)
  • 5.2.2 Global Metabolic Disorders Drugs Forecasted Revenue by Application (2024-2029)
  • 5.2.3 Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• 5.3 Global Metabolic Disorders Drugs Price by Application
  • 5.3.1 Global Metabolic Disorders Drugs Price by Application (2018-2023)
  • 5.3.2 Global Metabolic Disorders Drugs Price Forecast by Application (2024-2029)

6 US & Canada

• 6.1 US & Canada Metabolic Disorders Drugs Market Size by Type
  • 6.1.1 US & Canada Metabolic Disorders Drugs Sales by Type (2018-2029)
  • 6.1.2 US & Canada Metabolic Disorders Drugs Revenue by Type (2018-2029)
• 6.2 US & Canada Metabolic Disorders Drugs Market Size by Application
  • 6.2.1 US & Canada Metabolic Disorders Drugs Sales by Application (2018-2029)
  • 6.2.2 US & Canada Metabolic Disorders Drugs Revenue by Application (2018-2029)
• 6.3 US & Canada Metabolic Disorders Drugs Market Size by Country
  • 6.3.1 US & Canada Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 6.3.2 US & Canada Metabolic Disorders Drugs Sales by Country (2018-2029)
  • 6.3.3 US & Canada Metabolic Disorders Drugs Revenue by Country (2018-2029)
  • 6.3.4 US
  • 6.3.5 Canada

7 Europe

• 7.1 Europe Metabolic Disorders Drugs Market Size by Type
  • 7.1.1 Europe Metabolic Disorders Drugs Sales by Type (2018-2029)
  • 7.1.2 Europe Metabolic Disorders Drugs Revenue by Type (2018-2029)
• 7.2 Europe Metabolic Disorders Drugs Market Size by Application
  • 7.2.1 Europe Metabolic Disorders Drugs Sales by Application (2018-2029)
  • 7.2.2 Europe Metabolic Disorders Drugs Revenue by Application (2018-2029)
• 7.3 Europe Metabolic Disorders Drugs Market Size by Country
  • 7.3.1 Europe Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 7.3.2 Europe Metabolic Disorders Drugs Sales by Country (2018-2029)
  • 7.3.3 Europe Metabolic Disorders Drugs Revenue by Country (2018-2029)
  • 7.3.4 Germany
  • 7.3.5 France
  • 7.3.6 UK
  • 7.3.7 Italy
  • 7.3.8 Russia

8 China

• 8.1 China Metabolic Disorders Drugs Market Size
  • 8.1.1 China Metabolic Disorders Drugs Sales (2018-2029)
  • 8.1.2 China Metabolic Disorders Drugs Revenue (2018-2029)
• 8.2 China Metabolic Disorders Drugs Market Size by Application
  • 8.2.1 China Metabolic Disorders Drugs Sales by Application (2018-2029)
  • 8.2.2 China Metabolic Disorders Drugs Revenue by Application (2018-2029)

9 Asia (excluding China)

• 9.1 Asia Metabolic Disorders Drugs Market Size by Type
  • 9.1.1 Asia Metabolic Disorders Drugs Sales by Type (2018-2029)
  • 9.1.2 Asia Metabolic Disorders Drugs Revenue by Type (2018-2029)
• 9.2 Asia Metabolic Disorders Drugs Market Size by Application
  • 9.2.1 Asia Metabolic Disorders Drugs Sales by Application (2018-2029)
  • 9.2.2 Asia Metabolic Disorders Drugs Revenue by Application (2018-2029)
• 9.3 Asia Metabolic Disorders Drugs Sales by Region
  • 9.3.1 Asia Metabolic Disorders Drugs Revenue by Region: 2018 VS 2022 VS 2029
  • 9.3.2 Asia Metabolic Disorders Drugs Revenue by Region (2018-2029)
  • 9.3.3 Asia Metabolic Disorders Drugs Sales by Region (2018-2029)
  • 9.3.4 Japan
  • 9.3.5 South Korea
  • 9.3.6 China Taiwan
  • 9.3.7 Southeast Asia
  • 9.3.8 India

10 Middle East, Africa and Latin America

• 10.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Market Size by Type
  • 10.1.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2018-2029)
  • 10.1.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2018-2029)
• 10.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Market Size by Application
  • 10.2.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2018-2029)
  • 10.2.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2018-2029)
• 10.3 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country
  • 10.3.1 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country: 2018 VS 2022 VS 2029
  • 10.3.2 Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2018-2029)
  • 10.3.3 Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2018-2029)
  • 10.3.4 Brazil
  • 10.3.5 Mexico
  • 10.3.6 Turkey
  • 10.3.7 Israel
  • 10.3.8 GCC Countries

11 Company Profiles

• 11.1 Merck
  • 11.1.1 Merck Company Information
  • 11.1.2 Merck Overview
  • 11.1.3 Merck Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.1.4 Merck Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.1.5 Merck Recent Developments
• 11.2 Novartis
  • 11.2.1 Novartis Company Information
  • 11.2.2 Novartis Overview
  • 11.2.3 Novartis Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.2.4 Novartis Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.2.5 Novartis Recent Developments
• 11.3 Takeda Pharmaceutical
  • 11.3.1 Takeda Pharmaceutical Company Information
  • 11.3.2 Takeda Pharmaceutical Overview
  • 11.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.3.5 Takeda Pharmaceutical Recent Developments
• 11.4 Astra Zeneca
  • 11.4.1 Astra Zeneca Company Information
  • 11.4.2 Astra Zeneca Overview
  • 11.4.3 Astra Zeneca Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.4.4 Astra Zeneca Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.4.5 Astra Zeneca Recent Developments
• 11.5 Boehringer Ingelheim
  • 11.5.1 Boehringer Ingelheim Company Information
  • 11.5.2 Boehringer Ingelheim Overview
  • 11.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.5.5 Boehringer Ingelheim Recent Developments
• 11.6 KOWA
  • 11.6.1 KOWA Company Information
  • 11.6.2 KOWA Overview
  • 11.6.3 KOWA Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.6.4 KOWA Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.6.5 KOWA Recent Developments
• 11.7 Kythera
  • 11.7.1 Kythera Company Information
  • 11.7.2 Kythera Overview
  • 11.7.3 Kythera Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.7.4 Kythera Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.7.5 Kythera Recent Developments
• 11.8 Fuji yakuhin
  • 11.8.1 Fuji yakuhin Company Information
  • 11.8.2 Fuji yakuhin Overview
  • 11.8.3 Fuji yakuhin Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.8.4 Fuji yakuhin Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.8.5 Fuji yakuhin Recent Developments
• 11.9 LG Life Science
  • 11.9.1 LG Life Science Company Information
  • 11.9.2 LG Life Science Overview
  • 11.9.3 LG Life Science Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.9.4 LG Life Science Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.9.5 LG Life Science Recent Developments
• 11.10 Metsubishi Tanabe Pharma
  • 11.10.1 Metsubishi Tanabe Pharma Company Information
  • 11.10.2 Metsubishi Tanabe Pharma Overview
  • 11.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales, Price, Revenue and Gross Margin (2018-2023)
  • 11.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
  • 11.10.5 Metsubishi Tanabe Pharma Recent Developments

12 Industry Chain and Sales Channels Analysis

• 12.1 Metabolic Disorders Drugs Industry Chain Analysis
• 12.2 Metabolic Disorders Drugs Key Raw Materials
  • 12.2.1 Key Raw Materials
  • 12.2.2 Raw Materials Key Suppliers
• 12.3 Metabolic Disorders Drugs Production Mode & Process
• 12.4 Metabolic Disorders Drugs Sales and Marketing
  • 12.4.1 Metabolic Disorders Drugs Sales Channels
  • 12.4.2 Metabolic Disorders Drugs Distributors
• 12.5 Metabolic Disorders Drugs Customers

13 Market Dynamics

• 13.1 Metabolic Disorders Drugs Industry Trends
• 13.2 Metabolic Disorders Drugs Market Drivers
• 13.3 Metabolic Disorders Drugs Market Challenges
• 13.4 Metabolic Disorders Drugs Market Restraints

14 Key Findings in The Global Metabolic Disorders Drugs Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Author Details
• 15.3 Disclaimer

List of Tables

• Table 1. Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Table 2. Major Manufacturers of Glycogen Metabolism Disease Drug
• Table 3. Major Manufacturers of Lipid Metabolism Disease Drug
• Table 4. Major Manufacturers of Amino Acid Metabolism Drug
• Table 5. Major Manufacturers of Other
• Table 6. Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Table 7. Global Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 8. Global Metabolic Disorders Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 9. Global Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 10. Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2023)
• Table 11. Global Metabolic Disorders Drugs Revenue Market Share by Region (2024-2029)
• Table 12. Global Metabolic Disorders Drugs Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
• Table 13. Global Metabolic Disorders Drugs Sales by Region (2018-2023) & (K Units)
• Table 14. Global Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
• Table 15. Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2023)
• Table 16. Global Metabolic Disorders Drugs Sales Market Share by Region (2024-2029)
• Table 17. Global Metabolic Disorders Drugs Sales by Manufacturers (2018-2023) & (K Units)
• Table 18. Global Metabolic Disorders Drugs Sales Share by Manufacturers (2018-2023)
• Table 19. Global Metabolic Disorders Drugs Revenue by Manufacturers (2018-2023) & (US$ Million)
• Table 20. Global Metabolic Disorders Drugs Revenue Share by Manufacturers (2018-2023)
• Table 21. Global Key Players of Metabolic Disorders Drugs, Industry Ranking, 2021 VS 2022 VS 2023
• Table 22. Metabolic Disorders Drugs Price by Manufacturers 2018-2023 (USD/Unit)
• Table 23. Global Metabolic Disorders Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
• Table 24. Global Metabolic Disorders Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Metabolic Disorders Drugs as of 2022)
• Table 25. Global Key Manufacturers of Metabolic Disorders Drugs, Manufacturing Base Distribution and Headquarters
• Table 26. Global Key Manufacturers of Metabolic Disorders Drugs, Product Offered and Application
• Table 27. Global Key Manufacturers of Metabolic Disorders Drugs, Date of Enter into This Industry
• Table 28. Mergers & Acquisitions, Expansion Plans
• Table 29. Global Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 30. Global Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 31. Global Metabolic Disorders Drugs Sales Share by Type (2018-2023)
• Table 32. Global Metabolic Disorders Drugs Sales Share by Type (2024-2029)
• Table 33. Global Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 34. Global Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 35. Global Metabolic Disorders Drugs Revenue Share by Type (2018-2023)
• Table 36. Global Metabolic Disorders Drugs Revenue Share by Type (2024-2029)
• Table 37. Metabolic Disorders Drugs Price by Type (2018-2023) & (USD/Unit)
• Table 38. Global Metabolic Disorders Drugs Price Forecast by Type (2024-2029) & (USD/Unit)
• Table 39. Global Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 40. Global Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 41. Global Metabolic Disorders Drugs Sales Share by Application (2018-2023)
• Table 42. Global Metabolic Disorders Drugs Sales Share by Application (2024-2029)
• Table 43. Global Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 44. Global Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 45. Global Metabolic Disorders Drugs Revenue Share by Application (2018-2023)
• Table 46. Global Metabolic Disorders Drugs Revenue Share by Application (2024-2029)
• Table 47. Metabolic Disorders Drugs Price by Application (2018-2023) & (USD/Unit)
• Table 48. Global Metabolic Disorders Drugs Price Forecast by Application (2024-2029) & (USD/Unit)
• Table 49. US & Canada Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 50. US & Canada Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 51. US & Canada Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 52. US & Canada Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 53. US & Canada Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 54. US & Canada Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 55. US & Canada Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 56. US & Canada Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 57. US & Canada Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 58. US & Canada Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 59. US & Canada Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 60. US & Canada Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
• Table 61. US & Canada Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
• Table 62. Europe Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 63. Europe Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 64. Europe Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 65. Europe Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 66. Europe Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 67. Europe Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 68. Europe Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 69. Europe Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 70. Europe Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 71. Europe Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 72. Europe Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 73. Europe Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
• Table 74. Europe Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
• Table 75. China Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 76. China Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 77. China Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 78. China Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 79. China Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 80. China Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 81. China Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 82. China Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 83. Asia Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 84. Asia Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 85. Asia Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 86. Asia Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 87. Asia Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 88. Asia Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 89. Asia Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 90. Asia Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 91. Asia Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 92. Asia Metabolic Disorders Drugs Revenue by Region (2018-2023) & (US$ Million)
• Table 93. Asia Metabolic Disorders Drugs Revenue by Region (2024-2029) & (US$ Million)
• Table 94. Asia Metabolic Disorders Drugs Sales by Region (2018-2023) & (K Units)
• Table 95. Asia Metabolic Disorders Drugs Sales by Region (2024-2029) & (K Units)
• Table 96. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2018-2023) & (K Units)
• Table 97. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Type (2024-2029) & (K Units)
• Table 98. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2018-2023) & (US$ Million)
• Table 99. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Type (2024-2029) & (US$ Million)
• Table 100. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2018-2023) & (K Units)
• Table 101. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Application (2024-2029) & (K Units)
• Table 102. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2018-2023) & (US$ Million)
• Table 103. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Application (2024-2029) & (US$ Million)
• Table 104. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
• Table 105. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2018-2023) & (US$ Million)
• Table 106. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue by Country (2024-2029) & (US$ Million)
• Table 107. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2018-2023) & (K Units)
• Table 108. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales by Country (2024-2029) & (K Units)
• Table 109. Merck Company Information
• Table 110. Merck Description and Major Businesses
• Table 111. Merck Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 112. Merck Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 113. Merck Recent Developments
• Table 114. Novartis Company Information
• Table 115. Novartis Description and Major Businesses
• Table 116. Novartis Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 117. Novartis Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 118. Novartis Recent Developments
• Table 119. Takeda Pharmaceutical Company Information
• Table 120. Takeda Pharmaceutical Description and Major Businesses
• Table 121. Takeda Pharmaceutical Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 122. Takeda Pharmaceutical Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 123. Takeda Pharmaceutical Recent Developments
• Table 124. Astra Zeneca Company Information
• Table 125. Astra Zeneca Description and Major Businesses
• Table 126. Astra Zeneca Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 127. Astra Zeneca Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 128. Astra Zeneca Recent Developments
• Table 129. Boehringer Ingelheim Company Information
• Table 130. Boehringer Ingelheim Description and Major Businesses
• Table 131. Boehringer Ingelheim Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 132. Boehringer Ingelheim Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 133. Boehringer Ingelheim Recent Developments
• Table 134. KOWA Company Information
• Table 135. KOWA Description and Major Businesses
• Table 136. KOWA Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 137. KOWA Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 138. KOWA Recent Developments
• Table 139. Kythera Company Information
• Table 140. Kythera Description and Major Businesses
• Table 141. Kythera Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 142. Kythera Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 143. Kythera Recent Developments
• Table 144. Fuji yakuhin Company Information
• Table 145. Fuji yakuhin Description and Major Businesses
• Table 146. Fuji yakuhin Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 147. Fuji yakuhin Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 148. Fuji yakuhin Recent Developments
• Table 149. LG Life Science Company Information
• Table 150. LG Life Science Description and Major Businesses
• Table 151. LG Life Science Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 152. LG Life Science Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 153. LG Life Science Recent Developments
• Table 154. Metsubishi Tanabe Pharma Company Information
• Table 155. Metsubishi Tanabe Pharma Description and Major Businesses
• Table 156. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
• Table 157. Metsubishi Tanabe Pharma Metabolic Disorders Drugs Product Model Numbers, Pictures, Descriptions and Specifications
• Table 158. Metsubishi Tanabe Pharma Recent Developments
• Table 159. Key Raw Materials Lists
• Table 160. Raw Materials Key Suppliers Lists
• Table 161. Metabolic Disorders Drugs Distributors List
• Table 162. Metabolic Disorders Drugs Customers List
• Table 163. Metabolic Disorders Drugs Market Trends
• Table 164. Metabolic Disorders Drugs Market Drivers
• Table 165. Metabolic Disorders Drugs Market Challenges
• Table 166. Metabolic Disorders Drugs Market Restraints
• Table 167. Research Programs/Design for This Report
• Table 168. Key Data Information from Secondary Sources
• Table 169. Key Data Information from Primary Sources

List of Figures

• Figure 1. Metabolic Disorders Drugs Product Picture
• Figure 2. Global Metabolic Disorders Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 3. Global Metabolic Disorders Drugs Market Share by Type in 2022 & 2029
• Figure 4. Glycogen Metabolism Disease Drug Product Picture
• Figure 5. Lipid Metabolism Disease Drug Product Picture
• Figure 6. Amino Acid Metabolism Drug Product Picture
• Figure 7. Other Product Picture
• Figure 8. Global Metabolic Disorders Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
• Figure 9. Global Metabolic Disorders Drugs Market Share by Application in 2022 & 2029
• Figure 10. Hospital
• Figure 11. Retail Pharmacy
• Figure 12. Metabolic Disorders Drugs Report Years Considered
• Figure 13. Global Metabolic Disorders Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029
• Figure 14. Global Metabolic Disorders Drugs Revenue 2018-2029 (US$ Million)
• Figure 15. Global Metabolic Disorders Drugs Revenue Market Share by Region in Percentage: 2022 Versus 2029
• Figure 16. Global Metabolic Disorders Drugs Revenue Market Share by Region (2018-2029)
• Figure 17. Global Metabolic Disorders Drugs Sales 2018-2029 ((K Units)
• Figure 18. Global Metabolic Disorders Drugs Sales Market Share by Region (2018-2029)
• Figure 19. US & Canada Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
• Figure 20. US & Canada Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 21. Europe Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
• Figure 22. Europe Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 23. China Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
• Figure 24. China Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 25. Asia (excluding China) Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
• Figure 26. Asia (excluding China) Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 27. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales YoY (2018-2029) & (K Units)
• Figure 28. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue YoY (2018-2029) & (US$ Million)
• Figure 29. The Metabolic Disorders Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
• Figure 30. The Top 5 and 10 Largest Manufacturers of Metabolic Disorders Drugs in the World: Market Share by Metabolic Disorders Drugs Revenue in 2022
• Figure 31. Global Metabolic Disorders Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
• Figure 32. Global Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 33. Global Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 34. Global Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 35. Global Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 36. US & Canada Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 37. US & Canada Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 38. US & Canada Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 39. US & Canada Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 40. US & Canada Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
• Figure 41. US & Canada Metabolic Disorders Drugs Sales Share by Country (2018-2029)
• Figure 42. U.S. Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 43. Canada Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 44. Europe Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 45. Europe Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 46. Europe Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 47. Europe Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 48. Europe Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
• Figure 49. Europe Metabolic Disorders Drugs Sales Share by Country (2018-2029)
• Figure 50. Germany Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 51. France Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 52. UK Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 53. Italy Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 54. Russia Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 55. China Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 56. China Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 57. China Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 58. China Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 59. Asia Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 60. Asia Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 61. Asia Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 62. Asia Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 63. Asia Metabolic Disorders Drugs Revenue Share by Region (2018-2029)
• Figure 64. Asia Metabolic Disorders Drugs Sales Share by Region (2018-2029)
• Figure 65. Japan Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 66. South Korea Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 67. China Taiwan Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 68. Southeast Asia Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 69. India Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 70. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Market Share by Type (2018-2029)
• Figure 71. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Market Share by Type (2018-2029)
• Figure 72. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Market Share by Application (2018-2029)
• Figure 73. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Market Share by Application (2018-2029)
• Figure 74. Middle East, Africa and Latin America Metabolic Disorders Drugs Revenue Share by Country (2018-2029)
• Figure 75. Middle East, Africa and Latin America Metabolic Disorders Drugs Sales Share by Country (2018-2029)
• Figure 76. Brazil Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 77. Mexico Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 78. Turkey Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 79. Israel Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 80. GCC Countries Metabolic Disorders Drugs Revenue (2018-2029) & (US$ Million)
• Figure 81. Metabolic Disorders Drugs Value Chain
• Figure 82. Metabolic Disorders Drugs Production Process
• Figure 83. Channels of Distribution
• Figure 84. Distributors Profiles
• Figure 85. Bottom-up and Top-down Approaches for This Report
• Figure 86. Data Triangulation
• Figure 87. Key Executives Interviewed